Início › Câncer de Ovário › Louisiana
Ensaios clínicos de Câncer de Ovário em Louisiana
19 estudos para Câncer de Ovário estão buscando participantes em locais em Louisiana.
Cidades em Louisiana
Texto oficial do estudo (Inglês)
Phase 3 Trial Evaluating the Safety & Efficacy of IMNN-001 Administered in Combination w/ Standard NACT & Adjuvant Chemotherapy in Newly Diagnosed Patients w/ Advanced EOC, Fallopian Tube or Primary Peritoneal Cancer
- Louisiana State University HSC - NO Cancer Center, New Orleans
RecrutandoFase 3
Idades 18 e acima · Mulheres · Atualizado em 5 de out. de 2026 · NCT06915025Testing the Addition of Paclitaxel Administered Into the Abdominal Cavity Combined With Chemotherapy for Patients With Gastric Cancer Spread to the Abdominal Cavity
- University Medical Center New Orleans, New Orleans
RecrutandoFase 2/3
Idades 18 e acima · Todos os sexos · Atualizado em 5 de out. de 2026 · NCT07001748Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial
- Ochsner Medical Center Jefferson, New Orleans
RecrutandoFase 2
Todas as idades · Todos os sexos · Atualizado em 5 de out. de 2026 · NCT05564377Leveraging Methylated DNA Markers (MDMs) in the Detection of Endometrial Cancer, Ovarian Cancer, and Cervical Cancer
- Ochsner Clinic Foundation, New Orleans
RecrutandoEstudo observacional
Idades 18 e acima · Mulheres · Atualizado em 29 de set. de 2026 · NCT05051722A Study to Assess Anti-Tumor Activity of Intravenously (IV) Infused Carboplatin With Mirvetuximab Soravtansine in Participants With Newly Diagnosed Folate Receptor Alpha (FRα)Expressing Advanced-Stage Serous Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer.
- Women'S Cancer Care /ID# 276469, Covington
- University Medical Center New Orleans /ID# 274755, New Orleans
- Trials 365 /ID# 274310, Shreveport
RecrutandoFase 2
Idades 18 e acima · Mulheres · Atualizado em 29 de set. de 2026 · NCT06890338A Three-Part Phase 3 Study of Sofetabart Mipitecan in Participants With Platinum-Resistant (Part A) and Platinum-Sensitive (Parts B and C) Ovarian Cancer
- Ochsner Clinic Foundation, New Orleans
- Trials 365, Shreveport
RecrutandoFase 3
Idades 18 e acima · Todos os sexos · Atualizado em 22 de set. de 2026 · NCT07213804A Study to Assess Adverse Events and Change in Disease Activity of Multiple Treatment Combinations With Intravenous Mirvetuximab Soravtansine in Adult Participants With Ovarian Cancer
- Our Lady of the Lake Physician Group - Medical Oncology /ID# 277440, Baton Rouge
RecrutandoFase 2
Idades 18 e acima · Mulheres · Atualizado em 22 de set. de 2026 · NCT07059845A Clinical Trial of Sac-TMT in People With Non-HRD Positive Advanced Ovarian Cancer (MK-2870-021)
- Women's Cancer Care ( Site 0018), Covington
RecrutandoFase 3
Idades 18 e acima · Mulheres · Atualizado em 17 de set. de 2026 · NCT07318558Study to Evaluate INCB123667 Versus Investigator's Choice of Chemotherapy in Participants With Platinum-Resistant Ovarian Cancer With Cyclin E1 Overexpression
- Women'S Cancer Care, Covington
- Trials365, Llc, Shreveport
RecrutandoFase 3
Idades 18 e acima · Mulheres · Atualizado em 15 de set. de 2026 · NCT07214779A Study of INCB123667 in Participants With Platinum-Resistant Ovarian Cancer With Cyclin E1 Overexpression
- Trials365, Llc, Shreveport
RecrutandoFase 2
Idades de 18 a 99 · Mulheres · Atualizado em 15 de set. de 2026 · NCT07023627ORACLE: Observation of ResiduAl Cancer With Liquid Biopsy Evaluation
- Tulane Cancer Center, New Orleans
- Christus Highland/ Boniol, Shreveport
RecrutandoEstudo observacional
Idades 18 e acima · Todos os sexos · Atualizado em 14 de set. de 2026 · NCT05059444A Study to Evaluate the Efficacy and Safety of Sacituzumab Tirumotecan (MK-2870) Maintenance Treatment Versus Standard of Care in Participants With Platinum-sensitive Recurrent Ovarian Cancer (MK-2870-022/TroFuse-022/ENGOT-ov84/GOG-3103)
- Women's Cancer Care ( Site 0067), Covington
RecrutandoFase 3
Idades 18 e acima · Mulheres · Atualizado em 3 de set. de 2026 · NCT06824467A Study to Compare Two Surgical Procedures in Individuals With BRCA1 Mutations to Assess Reduced Risk of Ovarian Cancer
- West Jefferson Medical Center, Marrero
- Louisiana State University Health Science Center, New Orleans
- University Medical Center New Orleans, New Orleans
- e mais 1
Recrutando
Idades de 35 a 50 · Mulheres · Atualizado em 7 de ago. de 2026 · NCT04251052Testing Olaparib for One or Two Years, With or Without Bevacizumab, to Treat Ovarian Cancer
- LSU Health Baton Rouge-North Clinic, Baton Rouge
- Our Lady of the Lake Physician Group, Baton Rouge
- Our Lady of The Lake, Baton Rouge
- e mais 8
RecrutandoFase 3
Idades 18 e acima · Todos os sexos · Atualizado em 7 de ago. de 2026 · NCT06580314A Study of ART0380 for the Treatment of Advanced or Metastatic Solid Tumors
- Our Lady of the Lake, Baton Rouge
RecrutandoFase 1/2
Idades 18 e acima · Todos os sexos · Atualizado em 30 de jul. de 2026 · NCT04657068First-in-Human Study of Tersolisib (STX-478) as Monotherapy and in Combination With Other Antineoplastic Agents in Participants With Advanced Solid Tumors
- Louisiana State University Health Sciences Center, New Orleans
RecrutandoFase 1/2
Idades 18 e acima · Todos os sexos · Atualizado em 7 de jul. de 2026 · NCT05768139Study of Trastuzumab Deruxtecan With Bevacizumab Versus Bevacizumab Monotherapy for First-line Maintenance in HER2-Expressing Ovarian Cancer (DESTINY-Ovarian01)
- Trials365 LLC, Shreveport
RecrutandoFase 3
Idades 18 e acima · Mulheres · Atualizado em 2 de jul. de 2026 · NCT06819007Heated Intraperitoneal Chemotherapy Followed by Niraparib for Ovarian, Primary Peritoneal and Fallopian Tube Cancer
- LSU Health New Orleans, New Orleans
- University Medical Center New Orleans, New Orleans
RecrutandoFase 3
Idades 18 e acima · Mulheres · Atualizado em 16 de abr. de 2026 · NCT05659381SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
- Massive Bio SYNERGY-AI site, New Orleans
RecrutandoEstudo observacional
Todas as idades · Todos os sexos · Atualizado em 28 de out. de 2025 · NCT03452774Fonte: ClinicalTrials.gov, dados obtidos em 6 de out. de 2026. Cada estudo define seus próprios critérios de elegibilidade; a equipe do estudo decide quem pode participar.